Together, Ram and Carrie strengthen Kaléo’s leadership team as the Company continues to support its autoinjector portfolio, advance development programs aligned with emergency preparedness, and ...

The Furoscix on-body infusor. [Image courtesy of MannKind] MannKind (Nasdaq:MNKD) announced today that the FDA approved its Furoscix (furosemide) on-body infusor for pediatric patients. The company ...

Sempresto, Inc., a medical device company pioneering smartphone integrated rescue drug delivery, today announced the acquisition of Alerje’s mobile device integrated auto-injector platform, including ...

MannKind Corporation delivered strong Q3 '25 results, beating EPS and revenue estimates, and shares have responded positively. The FDA accepted the supplemental New Drug Application for the FUROSCIX ...

MannKind (Nasdaq:MNKD) announced that the FDA accepted a supplemental New Drug Application (sNDA) for its Furoscix ReadyFlow autoinjector. The Furoscix ReadyFlow autoinjector (SCP-111) was developed ...

A Prescription Drug User Fee Act target date of July 26, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application ...

Sempresto, Inc., a medical device company pioneering smartphone-integrated rescue drug delivery, today announced the acquisition of all patents and related physical and digital assets from inventor ...

TRENTON, NJ – Legislation sponsored by Senator Michael Testa (R-1) to expand access to epinephrine in schools, colleges, and youth camps has cleared the Senate Health, Human Services, and Senior ...

Auto-injector specialist Ypsomed is hopping on the U.S. manufacturing bandwagon, investing 200 million Swiss francs ($248 million) to build a plant in Holly Springs, North Carolina. It will be the ...

The next generation of autoinjectors must adapt through innovative design and manufacturing solutions. This webinar explores the key trends shaping autoinjector development, with a focus on ...